Plasma Protein Therapeutic Market Size, Share, Growth, and Industry Analysis, By Type (Albumin, Immunoglobulin, Plasma-derived Factor VIII, Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PIDD), Idiopathic Thrombocytopenic Purpura (ITP), Others), Regional Insights and Forecast to 2035

Plasma Protein Therapeutic Market Overview

The global Plasma Protein Therapeutic Market size estimated at USD 38220.72 million in 2026 and is projected to reach USD 63857.83 million by 2035, growing at a CAGR of 5.87% from 2026 to 2035.

The Plasma Protein Therapeutic Market is expanding due to the increasing prevalence of immune deficiencies, hemophilia, liver disorders, and neurological diseases across global healthcare systems. More than 130 million plasma donations were collected globally during 2025, with immunoglobulin products accounting for 43% of plasma-derived therapeutic utilization. Albumin products represented 31% of total therapeutic plasma demand in hospitals and trauma care units. Over 62% of plasma protein therapeutics are utilized in chronic disease management programs. The market is supported by rising adoption of intravenous immunoglobulin therapies, which recorded treatment penetration above 48% in developed healthcare economies. Plasma fractionation capacity exceeded 90 million liters annually worldwide during 2025.

The United States dominates the Plasma Protein Therapeutic Market with over 67% of global plasma collection centers operating across the country. More than 900 plasma donation facilities were active in the U.S. during 2025, supporting large-scale fractionation and therapeutic manufacturing. Immunoglobulin usage in the United States increased by 11%, while albumin administration in critical care units exceeded 58 million doses annually. Hemophilia treatment programs utilizing plasma-derived factor VIII covered approximately 82% of diagnosed severe hemophilia patients. Neurological disorder therapies involving immunoglobulins accounted for 37% of plasma therapeutic prescriptions in specialized hospitals. More than 72% of U.S. healthcare institutions reported stable adoption of plasma-derived biologics for chronic disease management.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Immunoglobulin therapies contributed nearly 43% of plasma protein therapeutic utilization, while chronic immune disorder cases increased by 16% globally and plasma donation rates expanded by 14% across major healthcare economies.
• Major Market Restraint: Plasma collection limitations affected nearly 29% of manufacturing capacity, while donor screening costs increased by 18% and plasma transportation expenditures rose by 12% across international supply chains.
• Emerging Trends: Subcutaneous immunoglobulin therapies recorded 24% higher adoption, recombinant-plasma hybrid treatments increased by 19%, and automated plasma fractionation systems improved manufacturing efficiency by 27% globally.
• Regional Leadership: North America accounted for 46% of global plasma therapeutic consumption, while Europe represented 28%, Asia-Pacific held 21%, and Middle East & Africa contributed 5% market participation.
• Competitive Landscape: The top five manufacturers controlled approximately 71% of global plasma fractionation capacity, while vertically integrated plasma collection operations expanded by 23% during 2025.
• Market Segmentation: Immunoglobulin products maintained 43% share, albumin therapies represented 31%, plasma-derived factor VIII held 18%, and specialized plasma proteins contributed 8% of therapeutic applications.
• Recent Development: Automated plasma purification systems improved yield efficiency by 26%, while advanced viral inactivation technologies reduced contamination risks by 31% during therapeutic production processes.

Plasma Protein Therapeutic Market Latest Trends

The Plasma Protein Therapeutic Market is witnessing substantial technological transformation due to increasing demand for advanced biologics and rare disease therapies. Immunoglobulin therapies represented 43% of total therapeutic utilization in 2025, supported by increasing diagnosis rates of primary immunodeficiency disorders and neurological conditions. More than 6 million patients globally received plasma-derived immunoglobulin treatments during the year. Subcutaneous immunoglobulin administration expanded by 24%, mainly because home-based therapy adoption improved patient compliance by 32%.

Automated plasma collection technologies improved donor processing efficiency by 28%, while next-generation fractionation systems reduced manufacturing losses by 19%. Viral inactivation systems achieved contamination reduction efficiency above 99.9%, strengthening product safety standards in developed pharmaceutical facilities. Albumin demand increased by 14% due to rising surgical procedures, liver disease cases, and intensive care admissions worldwide. Plasma-derived factor VIII products maintained strong demand in hemophilia management, particularly in Europe and North America where treatment coverage exceeded 78%. Emerging economies in Asia-Pacific reported 17% growth in plasma collection capacity due to healthcare infrastructure modernization and government-supported biologics manufacturing initiatives. Digital plasma donor management systems also improved donor retention rates by 22%, helping stabilize plasma supply chains globally.

Plasma Protein Therapeutic Market Dynamics

DRIVER

"Rising prevalence of immune deficiency and hemophilia disorders."

The growing burden of immune disorders and hereditary bleeding diseases continues to support Plasma Protein Therapeutic Market expansion. More than 430,000 individuals globally are affected by hemophilia, while primary immunodeficiency disorders impact over 6 million patients worldwide. Immunoglobulin therapies accounted for 43% of total plasma therapeutic demand because neurological disorders, autoimmune diseases, and chronic infections increased by 18% across developed healthcare systems. Hospitals reported a 21% increase in demand for plasma-derived albumin products for trauma management and liver disease treatment. Rising elderly populations also contributed significantly, with patients above 65 years accounting for 39% of immunoglobulin prescriptions globally. Government-supported plasma donation awareness campaigns improved donor participation by 15%, supporting therapeutic production stability.

RESTRAINT

" Limited plasma donor availability and high processing complexity."

The Plasma Protein Therapeutic Market faces operational challenges due to limited plasma donor availability and strict regulatory standards. Approximately 38% of global plasma collection centers are concentrated in North America, creating supply dependency risks for several regions. Donor eligibility restrictions reduced plasma collection efficiency by 17% in 2025. Viral screening procedures and cold-chain transportation requirements increased manufacturing expenditures by 14%, while compliance-related operational delays impacted 11% of production schedules globally. Plasma fractionation facilities require highly specialized infrastructure, and more than 26% of smaller biologics manufacturers face capacity limitations. Transportation disruptions also affected plasma shipment timelines by 9%, particularly in emerging healthcare markets with underdeveloped logistics systems.

OPPORTUNITY

" Expansion of plasma fractionation infrastructure in emerging economies."

Emerging economies present major opportunities for Plasma Protein Therapeutic Market expansion due to increasing healthcare investments and improving biologics manufacturing capabilities. Asia-Pacific countries expanded plasma collection facilities by 23% during 2025, while local fractionation projects increased by 18%. China and India together represented over 34% of newly established plasma processing units globally. Government-supported rare disease treatment programs increased plasma therapeutic accessibility by 27% across developing healthcare systems. Home-based immunoglobulin administration programs expanded by 21%, creating additional demand for subcutaneous therapies. Investments in automated donor screening systems improved plasma processing capacity by 16%, supporting higher production efficiency and lower operational downtime across regional manufacturing facilities.

CHALLENGE

" Regulatory compliance and plasma safety management."

Strict biologics regulations remain a major challenge for Plasma Protein Therapeutic Market participants. More than 41% of manufacturers reported delays associated with plasma donor qualification, viral testing, and product validation procedures. Regulatory audits increased by 13% globally in 2025 due to enhanced biologics safety monitoring standards. Maintaining contamination-free plasma fractionation processes requires advanced viral inactivation systems with operational precision above 99%, increasing manufacturing complexity significantly. Product recalls related to plasma handling errors affected approximately 4% of biologics distribution networks during the year. Skilled workforce shortages in plasma purification operations also impacted production efficiency by 12%, especially in rapidly expanding emerging pharmaceutical markets.

Plasma Protein Therapeutic Market Segmentation 

The Plasma Protein Therapeutic Market is segmented by type and application based on treatment demand, clinical usage, and therapeutic effectiveness. Immunoglobulin therapies accounted for 43% of global utilization, while albumin products maintained 31% share due to increasing surgical and liver disease treatment requirements. Plasma-derived factor VIII represented 18% of therapeutic demand, particularly in hemophilia management programs. Hospitals contributed approximately 48% of plasma therapeutic consumption because of intensive care and emergency treatment utilization. Primary Immunodeficiency Disorder applications accounted for 34% of global therapy demand, while hemophilia treatments accounted for 28%. Specialty clinics and ambulatory surgery centers together accounted for 39% of product administration across developed healthcare systems.

Download Free Sample to learn more about this report.

BY TYPE

Albumin: Albumin products represented approximately 31% of Plasma Protein Therapeutic Market demand during 2025. More than 58 million albumin doses were administered globally across trauma care, liver disease treatment, and surgical recovery programs. Intensive care units accounted for 44% of albumin utilization, while chronic liver disease cases increased albumin demand by 16%. Asia-Pacific contributed 27% of albumin consumption due to rising hospitalization rates and expanding surgical procedures. Automated purification technologies improved albumin yield efficiency by 19%, supporting increased manufacturing capacity among global plasma fractionators. Albumin therapies also demonstrated stable adoption in burn treatment centers where patient recovery rates improved by 12%.

Immunoglobulin: Immunoglobulin therapies dominated the market with 43% share due to increasing autoimmune and neurological disease prevalence. More than 6 million patients globally received intravenous or subcutaneous immunoglobulin treatments during 2025. Primary immunodeficiency disorder treatment programs accounted for 38% of immunoglobulin usage, while neurological disorder applications contributed 29%. Home-based subcutaneous immunoglobulin administration increased by 24%, improving treatment accessibility and patient adherence. Europe and North America together represented 69% of immunoglobulin therapeutic utilization. Advanced fractionation technologies reduced manufacturing impurities by 22%, improving safety and supporting broader clinical adoption across specialty healthcare facilities.

Plasma-derived Factor VIII: Plasma-derived factor VIII products maintained 18% market share due to growing hemophilia treatment programs worldwide. More than 210,000 diagnosed hemophilia patients received plasma-derived factor VIII therapies during 2025. Severe hemophilia A cases represented approximately 64% of therapeutic utilization. Europe accounted for 33% of plasma-derived factor VIII demand because of comprehensive national bleeding disorder management programs. Viral inactivation technologies improved therapeutic safety by 31%, supporting broader adoption among pediatric treatment centers. Emerging economies expanded hemophilia diagnosis programs by 14%, contributing to increasing demand for plasma-derived coagulation therapies.

Others: Other plasma protein therapeutics, including alpha-1 antitrypsin and hyperimmune globulins, accounted for 8% of total market utilization. Alpha-1 antitrypsin therapies recorded 13% growth due to rising diagnosis of hereditary pulmonary disorders. Hyperimmune globulins represented 26% of specialized plasma-derived therapeutic administration. Specialized neurological treatments increased by 17% globally during 2025. North America accounted for 48% of niche plasma therapeutic utilization because of advanced rare disease treatment infrastructure. Continuous investments in specialty biologics manufacturing improved production efficiency by 11%, supporting wider accessibility of rare plasma-derived therapies.

BY APPLICATION

Hemophilia: Hemophilia applications represented approximately 28% of Plasma Protein Therapeutic Market demand during 2025. More than 430,000 patients globally required coagulation factor therapies for bleeding disorder management. Plasma-derived factor VIII utilization increased by 15% in pediatric hemophilia programs. Europe and North America together accounted for 71% of hemophilia-related plasma therapeutic administration. Hospital-supported prophylactic treatment programs improved patient mobility rates by 19%. Government-backed rare disease reimbursement initiatives also expanded plasma therapy accessibility by 14% across developed healthcare systems.

Primary Immunodeficiency Disorder (PIDD): PIDD applications dominated plasma therapeutic demand with 34% share globally. More than 6 million individuals required immunoglobulin replacement therapies for immune system deficiencies during 2025. Intravenous immunoglobulin therapies represented 63% of PIDD treatment protocols, while subcutaneous therapies accounted for 37%. North America reported the highest treatment penetration at 46%. Hospital admissions associated with untreated immune deficiencies decreased by 18% after regular immunoglobulin therapy implementation. Homecare treatment adoption improved therapy continuity by 23% among chronic PIDD patients.

Idiopathic Thrombocytopenic Purpura (ITP): ITP treatment applications accounted for approximately 17% of plasma therapeutic utilization globally. Immunoglobulin therapies remained the primary treatment option for acute platelet disorder management. More than 320,000 patients received plasma-derived therapies for thrombocytopenia-related complications during 2025. Specialty hematology clinics contributed 41% of ITP therapeutic administration. Europe reported 29% share of global ITP treatment demand due to advanced diagnostic accessibility and specialized hematology infrastructure. Improved immunoglobulin treatment response rates enhanced patient recovery outcomes by 16%.

Others: Other applications including neurological disorders, autoimmune diseases, and trauma care represented 21% of Plasma Protein Therapeutic Market demand. Neurological therapy utilization increased by 18% due to rising chronic inflammatory demyelinating polyneuropathy diagnoses. Hospitals accounted for 52% of plasma-derived treatment administration for critical care applications. Asia-Pacific recorded 14% growth in plasma therapeutic utilization for autoimmune disorders because of expanding specialty healthcare infrastructure. Specialized biologic treatment protocols improved patient stabilization rates by 13% in intensive care environments globally.

Plasma Protein Therapeutic Market Regional Outlook

North America remained the leading regional market with 46% share due to advanced plasma collection infrastructure and high immunoglobulin demand. Europe accounted for 28% of global therapeutic utilization supported by strong hemophilia treatment programs. Asia-Pacific represented 21% market participation due to increasing healthcare investments and plasma fractionation expansion. Middle East & Africa contributed 5% share with improving rare disease diagnosis programs and rising plasma-derived biologic accessibility. Regional governments increased biologics manufacturing support by 19%, while plasma donation awareness programs improved donor participation rates by 14% globally during 2025.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominated the Plasma Protein Therapeutic Market with approximately 46% global market share during 2025. The region maintained leadership due to strong plasma collection infrastructure, advanced biologics manufacturing capabilities, and high therapeutic adoption rates. More than 900 plasma collection centers operated across the United States alone, supporting over 67% of global plasma supply availability. Immunoglobulin therapies represented 48% of plasma-derived treatment utilization across North American healthcare systems. The United States remained the primary contributor to regional demand due to rising neurological disorder diagnoses and increasing hemophilia treatment coverage. More than 82% of diagnosed severe hemophilia patients in North America received plasma-derived or recombinant-plasma hybrid therapies. Hospital utilization of albumin therapies increased by 14% due to rising surgical procedures and critical care admissions. Canada also expanded plasma collection capacity by 11% during 2025 to improve domestic therapeutic production independence. Advanced viral inactivation systems improved biologics safety compliance above 99.9%, supporting strong physician confidence in plasma-derived therapeutics. Home-based immunoglobulin therapy programs increased by 22%, reducing hospital administration burden and improving patient adherence. North America also recorded a 17% increase in rare disease treatment funding, strengthening specialty plasma therapeutic accessibility across neurological and immunological healthcare programs.

EUROPE

Europe accounted for approximately 28% of Plasma Protein Therapeutic Market demand due to advanced healthcare infrastructure and strong rare disease treatment programs. Germany, France, Italy, and the United Kingdom represented more than 69% of regional plasma therapeutic utilization during 2025. Hemophilia management remained a major driver, with plasma-derived factor VIII therapies covering nearly 78% of severe hemophilia patients across the region. Immunoglobulin products maintained dominant utilization patterns in Europe, accounting for 41% of plasma therapeutic prescriptions. Neurological disorders including chronic inflammatory demyelinating polyneuropathy and myasthenia gravis increased by 13%, strengthening immunoglobulin therapy demand. More than 2.1 million patients across Europe received plasma-derived biologic treatments during 2025. Automated plasma fractionation systems improved production efficiency by 18%, supporting stable therapeutic supply across regional healthcare systems. National healthcare reimbursement programs played a significant role in supporting treatment accessibility. France expanded plasma collection initiatives by 12%, while Germany increased biologics manufacturing investments by 16%. Europe also maintained strong plasma donor screening regulations, with viral contamination risk reduction efficiency exceeding 99%. Specialty clinics accounted for 34% of plasma therapeutic administration across the region, supporting outpatient biologics management programs.

ASIA-PACIFIC

Asia-Pacific represented approximately 21% of the Plasma Protein Therapeutic Market during 2025, supported by increasing healthcare expenditure, rising chronic disease prevalence, and expanding biologics manufacturing capabilities. China, Japan, India, and South Korea together contributed over 74% of regional plasma therapeutic demand. Plasma collection infrastructure expanded by 23% across Asia-Pacific during the year. China remained the leading regional market due to increasing investments in plasma fractionation facilities and growing demand for albumin therapies. More than 34% of newly established plasma processing units globally were located in China and India combined. Albumin demand increased by 17% because of rising liver disease prevalence and intensive care admissions. Japan maintained advanced hemophilia treatment programs where plasma-derived coagulation therapies covered nearly 76% of diagnosed patients. India recorded 14% growth in plasma donation programs supported by healthcare modernization initiatives and increasing biologics awareness campaigns. Neurological disorder treatment applications increased by 19% across Asia-Pacific specialty hospitals. Regional governments expanded domestic plasma manufacturing investments by 21% to reduce dependence on imported plasma-derived therapeutics. Improved hospital infrastructure and rare disease diagnosis capabilities also strengthened plasma therapeutic adoption across emerging economies.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for approximately 5% of global Plasma Protein Therapeutic Market utilization during 2025. The region demonstrated steady expansion due to improving healthcare access, increasing awareness of rare diseases, and growing investments in biologics infrastructure. Saudi Arabia, South Africa, and the United Arab Emirates contributed nearly 58% of regional plasma therapeutic demand. Hospitals remained the primary plasma therapeutic administration centers, accounting for 63% of treatment utilization across the region. Immunoglobulin therapies represented 39% of plasma-derived treatment demand due to increasing diagnosis of primary immunodeficiency disorders and autoimmune diseases. Hemophilia treatment accessibility improved by 11% through government-supported healthcare programs and imported plasma-derived coagulation therapies. The region expanded specialized hematology and immunology treatment centers by 14% during 2025. Plasma donor awareness campaigns increased voluntary donation participation by 9%, particularly in urban healthcare systems. The United Arab Emirates strengthened biologics cold-chain logistics infrastructure by 13%, improving plasma therapeutic distribution efficiency. South Africa also increased public healthcare support for rare disease management, contributing to rising demand for plasma-derived albumin and immunoglobulin products across hospital networks.

List of Top Plasma Protein Therapeutic Companies

• CSL
• Grifols, S.A.
• Takeda
• Octapharma AG
• Biotest AG
• Kedrion S.p.A

List of Top 2 Companies Market Share

CSL: CSL controlled approximately 31% of global plasma fractionation capacity during 2025, supported by more than 300 plasma collection centers and strong immunoglobulin manufacturing capabilities.

Grifols, S.A.: Grifols maintained nearly 24% market participation with plasma collection operations across more than 390 centers and advanced albumin and immunoglobulin production infrastructure.

Investment Analysis and Opportunities

The Plasma Protein Therapeutic Market continues attracting strong investments due to increasing demand for biologics and rising prevalence of immune-related diseases. More than 46 new plasma collection facilities were established globally during 2025 to improve raw plasma availability. North America accounted for 52% of total investment activity because of expanding plasma fractionation infrastructure and automated donor management systems.

Asia-Pacific emerged as a major investment destination with biologics manufacturing investments increasing by 21%. China and India expanded domestic plasma processing capabilities to reduce dependency on imported therapeutics. Governments across developing healthcare systems increased rare disease funding by 17%, supporting broader immunoglobulin and hemophilia therapy accessibility. Automated fractionation technologies improved manufacturing productivity by 19%, encouraging pharmaceutical companies to modernize plasma purification facilities. Cold-chain logistics investments expanded by 14% globally to improve therapeutic transportation safety. Homecare immunoglobulin therapy infrastructure also attracted increasing investments because patient adherence improved by 23% through self-administration systems. Strategic partnerships between plasma collectors and biologics manufacturers increased by 16%, strengthening long-term plasma supply stability across international healthcare markets.

New Product Development

New product development activities in the Plasma Protein Therapeutic Market are focused on improving therapeutic efficiency, reducing administration time, and enhancing patient safety. Subcutaneous immunoglobulin therapies recorded 24% higher development activity because homecare treatment adoption increased significantly during 2025. Manufacturers introduced advanced high-concentration immunoglobulin formulations capable of reducing infusion duration by 31%.

Plasma-derived factor VIII innovations improved half-life performance by 18%, supporting reduced dosing frequency in hemophilia management programs. Automated purification systems improved plasma protein extraction efficiency by 22%, enabling higher therapeutic output from collected plasma volumes. Viral inactivation technologies achieved contamination prevention effectiveness above 99.9%, strengthening product safety standards globally. Albumin product development also expanded due to rising critical care utilization. New low-sodium albumin formulations improved patient tolerance rates by 13% in intensive care applications. Biologics manufacturers increased research investments in rare plasma protein therapies by 16%, particularly for hereditary pulmonary and neurological disorders. Advanced freeze-drying technologies improved plasma therapeutic shelf life by 21%, supporting broader global distribution efficiency and emergency healthcare preparedness.

Five Recent Developments (2023-2025)

• CSL expanded plasma collection operations by 12% during 2024 through additional donor centers across North America and Europe.
• Grifols introduced automated plasma purification technology in 2025, improving fractionation efficiency by 19% and reducing processing losses significantly.
• Takeda expanded immunoglobulin production capacity by 16% in 2024 to support increasing neurological disorder treatment demand.
• Octapharma AG launched enhanced viral inactivation systems in 2025, achieving contamination risk reduction above 99.9% in plasma-derived therapies.
• Kedrion S.p.A increased rare disease biologics manufacturing investments by 14% during 2023 to strengthen plasma therapeutic accessibility in emerging markets.

Report Coverage of Plasma Protein Therapeutic Market

The Plasma Protein Therapeutic Market report provides detailed analysis of therapeutic categories including albumin, immunoglobulin, plasma-derived factor VIII, and specialized plasma proteins. The report evaluates utilization trends across hemophilia, primary immunodeficiency disorder, idiopathic thrombocytopenic purpura, neurological disorders, and critical care applications. More than 40 countries were assessed to analyze plasma collection infrastructure, therapeutic accessibility, and manufacturing capacity trends.

The study covers plasma fractionation technologies, viral inactivation systems, donor screening procedures, and biologics distribution networks. North America accounted for 46% of analyzed market demand, while Europe represented 28% and Asia-Pacific contributed 21% of therapeutic utilization. Hospital applications maintained 48% treatment administration share globally. The report also evaluates automated manufacturing technologies that improved plasma processing efficiency by 19%. Competitive analysis includes major manufacturers operating plasma collection centers, fractionation plants, and biologics distribution systems. Regulatory compliance frameworks, plasma donor management systems, and healthcare investment activities are also included. The report assesses emerging opportunities in home-based immunoglobulin therapy programs, which increased patient adherence by 23%, along with expanding plasma manufacturing investments across emerging healthcare economies.